These transgenic mice express the SV40 large T antigen gene (<i>TAg</i>) under the direction of the tetracycline-responsive element and a cytomegalovirus minimal promoter.  When mated to a mutant strain expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA), expression of <i>TAg</i> may be regulated with the tetracycline analog doxycycline in the double mutant offspring.  Mice that are hemizygous for the transgene are viable, normal in size and do not display any gross physical or behavioral abnormalities.  The Donating Investigator has not attempted to make this strain homozygous.
When crossed with a Tg(Ins2-rtTA)2Efr strain (e.g. Stock No. <a href="https://www.jax.org/strain/008250">008250</a>), double transgenic mice treated with doxycycline develop hypoglycemia and multiple pancreatic insulinomas.


Use of MICE by companies or for-profit entities requires a license prior to shipping.

These tet-Tag transgenic mice express the SV40 large T antigen under the direction of the tetracycline operator. These mice may be useful for studying tumorigenesis and cancer progression.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.